These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 35561484)

  • 21. Buprenorphine physician-pharmacist collaboration in the management of patients with opioid use disorder: results from a multisite study of the National Drug Abuse Treatment Clinical Trials Network.
    Wu LT; John WS; Ghitza UE; Wahle A; Matthews AG; Lewis M; Hart B; Hubbard Z; Bowlby LA; Greenblatt LH; Mannelli P;
    Addiction; 2021 Jul; 116(7):1805-1816. PubMed ID: 33428284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of Receipt of Opioid Use Disorder-Related Telehealth Services and Medications for Opioid Use Disorder With Fatal Drug Overdoses Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM; Shoff C; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Psychiatry; 2023 May; 80(5):508-514. PubMed ID: 36988913
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The estimated impact of state-level support for expanded delivery of substance use disorder treatment during the COVID-19 pandemic.
    Nesoff ED; Marziali ME; Martins SS
    Addiction; 2022 Jun; 117(6):1781-1786. PubMed ID: 34873783
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Study protocol for the Respond to Prevent Study: a multi-state randomized controlled trial to improve provision of naloxone, buprenorphine and nonprescription syringes in community pharmacies.
    Green TC; Bratberg J; Irwin AN; Boggis J; Gray M; Leichtling G; Bolivar D; Floyd A; Al-Jammali Z; Arnold J; Hansen R; Hartung D
    Subst Abus; 2022; 43(1):901-905. PubMed ID: 35213293
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Experiences of Opioid Use Disorder Patients Receiving Buprenorphine Through a Telehealth Program.
    Moore DJ; Goyal D; Rodriguez L
    J Addict Nurs; 2021 Jul-Sep 01; 32(3):205-210. PubMed ID: 34473450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Research Priorities for Expansion of Opioid Use Disorder Treatment in the Community Pharmacy.
    Jarrett JB; Bratberg J; Burns AL; Cochran G; DiPaula BA; Legreid Dopp A; Elmes A; Green TC; Hill LG; Homsted F; Hsia SL; Matthews ML; Ghitza UE; Wu LT; Bart G
    Subst Abus; 2023 Oct; 44(4):264-276. PubMed ID: 37902032
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The intertwined expansion of telehealth and buprenorphine access from a prescriber hub.
    Moore DT; Wischik DL; Lazar CM; Vassallo GG; Rosen MI
    Prev Med; 2021 Nov; 152(Pt 2):106603. PubMed ID: 33974959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic.
    Peckham AM; Ball J; Colvard MD; Dadiomov D; Hill LG; Nichols SD; Tallian K; Ventricelli DJ; Tran TH
    Am J Health Syst Pharm; 2021 Mar; 78(7):613-618. PubMed ID: 33411894
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patient perceptions of and experiences with stigma using telehealth for opioid use disorder treatment: a qualitative analysis.
    Couch JV; Whitcomb M; Buchheit BM; Dorr DA; Malinoski DJ; Korthuis PT; Ono SS; Levander XA
    Harm Reduct J; 2024 Jun; 21(1):125. PubMed ID: 38937779
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Barriers and facilitators to nurse practitioner buprenorphine prescribing for opioid use disorder in primary care settings.
    Speight C; Caiola C; Tyndall DE; Scott ES
    J Am Assoc Nurse Pract; 2023 Feb; 35(2):112-121. PubMed ID: 36512806
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic.
    Cochran G; Bruneau J; Cox N; Gordon AJ
    Subst Abus; 2020; 41(3):269-274. PubMed ID: 32697171
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increasing buprenorphine access for veterans with opioid use disorder in rural clinics using telemedicine.
    Brunet N; Moore DT; Lendvai Wischik D; Mattocks KM; Rosen MI
    Subst Abus; 2022; 43(1):39-46. PubMed ID: 32078492
    [No Abstract]   [Full Text] [Related]  

  • 33. Primary Care Providers' Experiences Treating Opioid Use Disorder Using Telehealth in the Height of the COVID-19 Pandemic.
    Marshall SA; Siebenmorgen LE; Youngen K; Borders T; Zaller N
    J Prim Care Community Health; 2024; 15():21501319241246359. PubMed ID: 38600789
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Broadband access and telemedicine adoption for opioid use disorder treatment in the United States.
    Ali MM; Ghertner R
    J Rural Health; 2023 Jan; 39(1):233-239. PubMed ID: 35838414
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Utilization of Telehealth Solutions for Patients with Opioid Use Disorder Using Buprenorphine: A Scoping Review.
    Guillen AG; Reddy M; Saadat S; Chakravarthy B
    Telemed J E Health; 2022 Jun; 28(6):761-767. PubMed ID: 34714172
    [No Abstract]   [Full Text] [Related]  

  • 36. Treatment of opioid use disorder during COVID-19: Experiences of clinicians transitioning to telemedicine.
    Uscher-Pines L; Sousa J; Raja P; Mehrotra A; Barnett M; Huskamp HA
    J Subst Abuse Treat; 2020 Nov; 118():108124. PubMed ID: 32893047
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Telehealth to improve continuity for patients receiving buprenorphine treatment for opioid use disorder.
    Sahu N; Chen PH; Shimoni N
    Ann Fam Med; 2022 Apr; 20(20 Suppl 1):. PubMed ID: 35947491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Geographic Distribution of Providers With a DEA Waiver to Prescribe Buprenorphine for the Treatment of Opioid Use Disorder: A 5-Year Update.
    Andrilla CHA; Moore TE; Patterson DG; Larson EH
    J Rural Health; 2019 Jan; 35(1):108-112. PubMed ID: 29923637
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patient satisfaction with clinic-based medication pick up: Addressing pharmacy-level challenges to buprenorphine access.
    Kolb E; Rueth M
    J Opioid Manag; 2021; 17(7):77-86. PubMed ID: 34520029
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Understanding opportunities and challenges with telemedicine-delivered buprenorphine during the COVID-19 pandemic.
    Mattocks KM; Moore DT; Wischik DL; Lazar CM; Rosen MI
    J Subst Abuse Treat; 2022 Aug; 139():108777. PubMed ID: 35346533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.